Through merger together on the course to success
Aevona Group, with its headquarters in Pähl near Munich, is with a turnover of 500 million € und 2,500 employees in 13 locations in 7 countries, the leading provider in the development, manufacturing and marketing of medicines and nutritional supplements in Europe. With nine production locations (including Regensburg), a turnover of 282 million € and 2,000 employees (of these almost 400 in the Regensburg plant) Haupt Pharma AG with its headquarters in Berlin is equally of one of the largest European enterprises for pharmaceutical project development and manufacturing.
As Aenova advised, the company has found a partner in Haupt Pharma AG, with which it can strategically expand its portfolio. There was agreement to maintain silence on the purchase price. The transaction is being financed with a combination of loan and equity capital. Both companies are now together setting up production locations in Germany and Europe and concurrently accelerating global alignment. The existing portfolio from Aenova in the field of solid, semisolid and liquid dosage forms will be complemented via the merger with Haupt Pharma’s fields in the sterile manufacture and processing of special active substances (hormones, antibiotics, cytostatics) for the pharmaceutical industry.
Via the merger a production network is coming into being in 21 locations with 4,000 empoyees and a total turnover of 750 millon €. The Regensburg location, which has grown in the last few years, is to be expanded in the future. Already today with almost 400 empoyees working here – again almost as many employees at the time of the closure of Bristol Meyers Squipp in 1995.
For further information see: